Status: Recruiting
GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
The third/fourth generation of CAR-T cells that target GPC3 (GPC3-CART cell) and/or soluble TGFβ (GPC3/TGFβ-CART )have been constructed and their anti-HCC function has been verified by multiple in vitro and in vivo studies. Clinical studies will be performed to test the anti-cancer function by the GPC3/TGFβ-CAR-T cells in human HCC patients with GPC3 expression. In this phase I study, the safety, tolerance, and preliminary efficacy of the GPC3/TGFβ-CAR-T cell immunotherapy on human will firstly be tested.
Participants needed: 30
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Second Affiliated Hospital of Guangzhou Medical UniversityUpdated: Jun 25, 2024Locations: 2
Eligibility criteria
patients with advanced HCC,which express GPC3 protein. [+5]
Had accepted gene therapy before; [+9]